GlassScriptPhysician profile
Robert O Spruill
NPI 1609808179
$13,712.23
in general payments reported to CMS, 2019-2025
56 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $1,375 · 2021: $2,189 · 2022: $2,237 · 2023: $2,088 · 2024: $1,918 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,341.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,933.13 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $1,856.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,388.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,047.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.10 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $740.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $652.93 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $492.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $436.87 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $436.61 | 2019-2024 | Gardasil 9, Vaxneuvance, Proquad |
| Allergan, INC. | $331.09 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.59 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $276.90 | 2019-2025 | |
| Lilly USA, LLC | $265.94 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.03 | 2019-2025 | Xifaxan |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spruill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.